Clinical Trials - Patient enrollment for the BX211 Phase 2 trial in Diabetic Foot Osteomyelitis (DFO) has been completed, with topline results expected in Q1 2025[2] - In the BX004 Phase 1b/2a trial, 14.3% of patients converted to sputum culture negative for Pseudomonas aeruginosa after 10 days of treatment, compared to 0% in the placebo arm[6] - The company expects to report topline results for the BX004 Phase 2b study in the first half of 2026 following resolved manufacturing delays[2] Financial Performance - BiomX reported a net income of $9.6 million for Q3 2024, compared to a net loss of $7.9 million in Q3 2023, primarily due to changes in the fair value of warrants[14] - Operating loss for the nine months ended September 30, 2024, was $27,838 million, compared to $20,076 million for the same period in 2023, indicating a 38.5% increase in losses[26] - Net loss for the three months ended September 30, 2024, was $9,642 million, compared to a net income of $7,906 million in the same period last year, marking a significant shift in performance[26] - Basic loss per share for the three months ended September 30, 2024, was $(0.31), compared to earnings of $1.30 per share in the same period last year[26] Expenses - Research and development expenses increased to $7.3 million in Q3 2024 from $5.6 million in Q3 2023, driven by preparations for the Phase 2b clinical trial of BX004 and increased expenses related to BX211[11] - General and administrative expenses rose to $3.2 million in Q3 2024 from $2.2 million in Q3 2023, attributed to the consolidation of expenses after the acquisition of Adaptive Phage Therapeutics[12] - Research and development (R&D) expenses for the three months ended September 30, 2024, were $7,279 million, up from $5,641 million in the same period last year, reflecting a 29% increase[26] Cash and Assets - Cash balance as of September 30, 2024, was $24.7 million, down from $30.7 million as of December 31, 2023, due to net cash used in operating activities[9] - BiomX estimates its cash and equivalents are sufficient to fund operations into the fourth quarter of 2025[9] - Total current assets increased to $28,316 million as of September 30, 2024, compared to $17,632 million as of December 31, 2023, representing a growth of 60.5%[24] - Total non-current assets rose to $31,664 million as of September 30, 2024, from $7,397 million as of December 31, 2023, an increase of 327%[24] - Total current liabilities decreased to $8,944 million as of September 30, 2024, from $11,176 million as of December 31, 2023, a reduction of 19.8%[25] Stock and Shareholder Information - The company conducted a 1-for-10 reverse stock split in August 2024, consolidating every ten shares into one[7] - The weighted average number of shares used in computing basic loss per share increased to 16,366,122 for the three months ended September 30, 2024, from 6,058,774 in the same period last year[26] Liabilities - The company reported a significant increase in operating lease liabilities, which rose to $8,651 million as of September 30, 2024, compared to $3,239 million as of December 31, 2023[25] - The company recorded a loss from the change in fair value of Private Placement Warrants amounting to $(20,559) million for the three months ended September 30, 2024[26]

BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF) is now expected to report topline results in H1 2026 following resolved manufacturing delays Company to host conference call and webcast today at 8:00AM ET NESS ZIONA, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and ...

BiomX Inc. (PHGE) recently announced the presentation of data from its Phase 1b/2a study for BX004 — a fixed multi-phage cocktail. BX004 is used for treating cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas aeruginosa (PsA). BiomX will present this study data at the North American Cystic Fibrosis Conference in Boston. PHGE Stock's Likely Trend Following the News Shares of PHGE rose 2.8% to $1.05 yesterday following the news. To date, BX004 has been under several trials. ...

GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present further data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented in two sessions at the North American Cystic Fibrosi ...

In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the reverse stock split GAITHERSBURG, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the reverse s ...

Core Insights - BiomX anticipates reporting significant results in 2025 for two clinical assets, BX004 and BX211, from its phage therapy pipeline [1][2] - The company has successfully converted Series X Non-Voting Convertible Preferred Stock into common stock following a stockholder vote [1][6] - BiomX will host a conference call and webcast to discuss its financial results and corporate updates [1][12] Clinical Program Updates - BX004 is a fixed phage cocktail targeting chronic pulmonary infections in cystic fibrosis patients, with positive Phase 1b/2a trial results presented at major conferences [3][4] - In the BX004 arm, 14.3% of patients achieved negative sputum cultures for P. aeruginosa after 10 days, compared to 0% in the placebo group [4] - A Phase 2b trial for BX004 is expected to start, with results anticipated in Q3 2025 [5][14] - BX211 is a personalized phage treatment for diabetic foot osteomyelitis, currently in a Phase 2 trial with initial results expected in Q1 2025 [5][16] Business Update - BiomX's stockholders approved the conversion of Series X Preferred Stock into common stock, resulting in the addition of 109,152,000 shares to the outstanding share count [6] - The company received an Acceptance Letter from NYSE American, granting until November 23, 2025, to regain compliance with listing standards [7] Financial Results - As of June 30, 2024, BiomX reported a cash balance of $32.7 million, an increase from $30.7 million a year prior, primarily due to a $50 million financing [8] - Research and development expenses for Q2 2024 were $6.9 million, up from $3.8 million in Q2 2023, reflecting increased clinical trial preparations [9] - General and administrative expenses rose to $2.8 million in Q2 2024 from $2.3 million in Q2 2023, attributed to the merger's full consolidation [10] - The company reported a net income of $4.5 million for Q2 2024, a significant improvement from a net loss of $6.4 million in Q2 2023 [11]

GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it intends to effect a one-for-ten reverse split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"). The Common Stock will continue to trade on the NYSE American under the existing symbol "PHGE" and will begin trading on a spli ...

"We are pleased the NYSE American has accepted our Plan to regain compliance," commented Jonathan Solomon, Chief Executive Officer of BiomX. "We intend to take all reasonable measures available to us and have already begun implementing our Plan, including by obtaining stockholders' approval for conversion of the Company's outstanding Series X Convertible Preferred Stock to Common Stock, as announced earlier this month." During the Plan Period, the Company will be subject to periodic review by the NYSE Ameri ...

GAITHERSBURG, Md., July 29, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received a notification (the "Acceptance Letter") from the NYSE American LLC (the "NYSE American"), dated July 23, 2024, stating that the NYSE American has accepted the Company's previously submitted plan to regain compliance with the NYSE American's l ...

BiomX's Series X Preferred Stock was issued upon BiomX's acquisition of Adaptive Phage Therapeutics, Inc. ("APT") and a concurrent $50 million financing (the "Financing"), which were consummated in March 2024. As a result of the stockholder vote approving the conversion of BiomX's Series X Preferred Stock, each share of Series X Preferred Stock issued in the APT acquisition and the private placement will be converted into 1,000 shares of BiomX common stock, subject to certain beneficial ownership limitation ...